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Abstract
Background: Colorectal cancer is the third most common type of cancer in men and women and the second
leading cause of cancer-related deaths in the United States and UK. Colorectal cancer is strongly related to age, with
almost three-quarters of cases occurring in people aged 65 or over. Pre-symptomatic screening is one of the most
powerful tools for preventing colorectal cancer. Recently, the use of mitochondrial tRNA genes mutation or
polymorphism patterns as a biomarker is rapidly expanding in different cancers because tRNA genes perform
several functions including processing and translation which are essential components of mitochondrial protein
synthesis. The aim of the present study was to find out the association of mitochondrial A12308G alteration in
tRNALeu(CUN) in colorectal cancer and its usage as a new biomarker screening test.
Methods: A tumor tissues from 30 patients who had colorectal cancer were selected randomly. The A12308G
alteration in tRNALeu (CUN) was screened in the 30 colorectal tumor tissues. For comparison, 100 blood samples
of healthy controls using PCR-sequencing methods were selected and the following results were found.
Result: The A12308G, a polymorphic mutation in V-loop tRNALeu(CUN), was found in 6 Colorectal tumor tissues and 3
healthy controls. A statistical significant difference was found between cases and control regarding the association of
the A12308G mutation with the colorectal tumor (P < 0.05).
Conclusions: The A12308G, a polymorphic mutation in V-loop tRNALeu(CUN), could be considered as pathogenic
mutation in combination with mitochondrial external conditions and other mitochondrial genes in developing
different diseases especially cancers and could be used as one of the diagnostic tool. Also it seems that maybe
there is relevance between A12308G mutation and other mutations that it can cause various phenotypes.
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Background
Worldwide, colorectal cancer (CRC) is the fourth most
common cancer and affects both men and women equally
and the American Cancer Society estimated that ~56,730
would die from this disease. The substantial mortality as-
sociated with this cancer makes it the leading cause of
gastrointestinal cancer deaths [1]. Colorectal cancer is an
uncontrolled cell division of the colon or rectal cells start-
ing in the inner most layer and can grow through some or
all of the other layers. These cells may also invade and
destroy the tissue around them and spread to form new
tumors in other parts of the body. Unfortunately, some
colorectal cancers might be present without any signs or
symptoms and often diagnosed late when the disease be-
comes more advanced. For this reason, it is very important
to have regular colorectal screening tests for early detec-
tion when the disease is easier to cure/control. Screening
has been found to be effective in reducing the incidence
and mortality of colorectal cancer through the detection
and removal of pre-cancerous lesions and through the de-
tection of CRC in its early stages. Colonoscopy, sigmoidos-
copy, and fecal occult blood tests are all recommended
screening tests that have widespread availability [2]. Re-
cently, Genetic testing is developed that offer more reliable
options for colorectal cancer screening. Mitochondria
play a central role in the regulation of cellular function,
metabolism, free radical generation, and cell death. Defects
in mitochondrial function have been speculated to have an
impact on the development and progression of cancer [3].
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Cancer development involves the accumulation of gen-
etic changes that will happen in both nuclear and mito-
chondrial genes. In cancer cells, mutations in mtDNA
were more readily detectable and 10 times abundant
than nuclear DNA (nDNA), possibly due to the lack of
introns, lack of histone protection, low efficiency of
mtDNA repair systems and close proximity to damaging
reactive oxygen species (ROS) [4–7].
Alterations in mitochondrial DNA (mtDNA) in the
D-loop region as well as in other parts of the mito-
chondrial genome, including point mutations, deletions,
insertions and genome copy number changes, are be-
lieved to be responsible for carcinogenesis in a variety
of human cancers such as ovarian, colon, thyroid and
endometrial cancer, salivary glands, liver, lung, gastric,
brain, bladder, kidney, prostate, head and neck, breast
cancer and leukemia [8–19].
Mutations in the Mt-tRNA genes have impact on the
secondary and tertiary tRNA structure, and may cause
transcriptional and translational defects and mitochon-
drial respiratory chain dysfunction consequently. More
than half of mitochondrial mutations have been located
in mt-tRNA genes which are hot spots for mitochondrial
pathogenesis [20].
Therefore, mtDNA mutation pattern is a great mo-
lecular cancer biomarkers and it could increase the spe-
cificity of cancer detection and prediction. Here, we are
studying about the human mitochondrial A12308G
alteration in tRNALeu(CUN) in tumoral tissues from colo-
rectal cancer patients.
Methods
Tumor tissues samples, from thirty Iranian colorectal
cancer patients were collected at the cancer institute of
Imam Khomeini Tehran hospital. For comparative
purposes, blood samples from100 healthy controls of
matched age and sex were collected too. The DNA from
tumoral tissues was extracted using QIAamp DNA FFPE
kit (QIAGENE) while, DNA from blood samples ob-
tained from healthy control was extracted using DNA
fast kit (Genefanavaran, Tehran, Iran). The A12308G al-
teration in tRNALeu(CUN) was screened by sequencing
the PCR products from both patients and control sam-
ples. Primer sequences are as described in Table 1 or
Additional file 1. PCR was carried out in a total vol-
ume of 25 μl, containing 2.5 mM Mgcl2, 200 μM of
each dNTP, 10 Pm of each primer, 100 ng total DNA and
1U taq DNA polymerase in thermal cyclers (Eppendrof,
Master cyclers, 5330). Thermocycling conditions were 94
°C for 5 min, followed by 32 cycles of 95 °C for 1 min,
annealing for1 min at 50 °C and extension at 72 °C
for 45 s, and finally 72 °C for 10 min for 32 cycles.
The PCR products were examined for specificity
using 1.5 % agarose gel electrophoresis. Double-
stranded automated sequencing was performed using
an ABI 3100 sequencing machine (Applied Biosystems,
Kavosh Fanavaran Kawsar Company, Iran). All fragments
were sequenced in both forward and reverse directions.
Sequence of tumoral tissues were analyzed using a
Finch TV program (chromatogram viewer which dis-
plays DNA sequence traces) and compared to the
Human Mitochondrial Reference Sequence NC_012920
provided by the National Center for Biotechnology Infor-
mation (NCBI). The Chi-square test was used with SPSS
(Statistical Package for the Social Sciences, version: 13) to
examine the association between the presence of muta-
tion/polymorphisms in colorectal tumoral tissues and
the blood of healthy controls. P values < 0.05 were
regarded as statistically significant.
Resutls
Homoplasmic A12308G, a polymorphic mutation in
V-loop (tRNALeu(CUN)), was found in 6 colorectal
tumor (20 %) and 3 healthy controls (3 %). This dif-
ference is statistically significant (P = 0.05).
Discussion
Various human diseases have been associated with
mtDNA mutations, indicating that dysfunction of the
components of oxidative phosphorylation encoded by
the mitochondrial genome can be deleterious [21].
Abnormalities in mtDNA have proven to be associated
with leber’s hereditary optic neuropathy (LHON) [22],
Primary open-angle glaucoma (POAG) [23, 24], pseu-
doexfoliation glaucoma (PEG), primary angle closure
glaucoma (PACG), other spontaneous optic neuropathies
[25–27] and male infertility [28]. Moreover, 25-80 % of
somatic mutations in mitochondrial DNA are found in
various neoplasms [29]. Also, in 2012 the role of the
mitochondrial tRNA genes was analyzed in patients with
asthma compared with a set of healthy controls. They
suggested that the mitochondrial tRNA genes play a key
role in asthma development [30]. The use of mtDNA
mutation patterns as a biomarker is rapidly expanding in
rare metabolic diseases, aging, cancer, tracing of human
migration patterns, population characterization and hu-
man identification in forensic science [31]. It seems that
the mitochondrial genome is more useful in detecting
tumor cells in body fluids and cytological specimens
than mutations in nuclear DNA had been confirmed.
In the present study, to the best of our knowledge, this is
the first reported association between colorectal cancer
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and mtDNA A12308G alteration in tRNALeu(CUN). The
A12308G change was introduced as a common poly-
morphism by Houshmand at the first time [14]. Several
studies described the association of mt-tRNA mutations
with human cancers. This mutation came to the atten-
tion of the breast cancer research communities as a
plausible candidate marker for increased breast cancer
susceptibility [29, 32]. In USA, the A12308G poly-
morphism was introduced as an important factor in
kidney and prostate cancer risk [16]. In India, the
A12308G mutation was seen as a significant change in
the risk of oral cancer [33]. This alteration was, also,
reported as a multiplier risk factor in advanced breast
cancer tumors in European – American patients [34].
Increased prevalence of the A12308G mutation in mito-
chondrial tRNALeu(CUN)gene associated with Friedreich's
ataxia in Iran, was reported [35]. In previous studies,
A12308G alteration has occurred in association with an-
other disease causing alteration in MELAS, myopathy
and primary congenital glaucoma (PCG) where three
such changes (G10398A, A12308G and G13708A) were
present in the later [36, 37]. Moreover, the A12308G
polymorphism in tRNALeu(CUN) increases the risk of de-
veloping stroke in patients with the A3243G mutation
[38]. So, this polymorphism may act as a secondary mu-
tation in this disease pathogenicity. The A12308G vari-
ation is also associated with increased ROS production
[39]. Nine main European haplotypes (H, I, J, K, T, U, V,
W and X) were analyzed in a series of patients with pros-
tate and renal cancers studied by Booker et al. Using the
A12308G substitution in tRNALeu as a marker of the
mtDNA haplogroup U, it was found that patients carry-
ing this haplogroup had an increased risk of renal and
prostate cancer [16]. Some studies showed an increased
frequency of the A12308G substitution in mitochondrial
patients carrying mtDNA single macrodeletion. In this
group of patients, A12308G substitution is associated
with a higher relative risk of developing pigmentary
retinal degeneration, short stature, dysphasia–dysarthria
and cardiac conduction defects [40]. Moreover, the
A12308G was found in 8 Alzheimer’s disease patients
[41]. In the case of endometrial adenocarcinoma the
presence of mitochondrial A12308G alteration in
tRNALeu(CUN) was reported [42, 43]. Study in Italy stated
that Mitochondrial DNA mutations have been causally
linked with cardiomyopathies, both dilated (DCM) and
hypertrophic. They identified the T12297C mutation in the
mtDNA-tRNALeu(CUN) of a patient diagnosed with DCM.
In the variable loop of the same tRNA, their patient also
carried the A12308G transition [44].
Conclusions
In conclusion, the present study revealed that mitochon-
drial research will enable to establish biomarkers helping
to identify individuals at high risk for developing specific
cancer types and to develop screening approaches for
early diagnosis of cancer. In addition, it seems that more
research is essentially needed to understand the effect
and role of the A12308G mutation as a common poly-
morphism or an inherited predisposition factor in the
carcinogenesis. We believe that this mutation associated
with other mutations and/or factors would lead to di-
verse phenotypes.
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